PURPOSE: Methotrexate (MTX) can cause significant clinical neurotoxicity and asymptomatic leukoencephalopathy. We sought to identify clinical, pharmacokinetic, and genetic risk factors for these MTX-related toxicities during childhood acute lymphoblastic leukemia (ALL) therapy and provide data on safety of intrathecal and high-dose MTX rechallenge in patients with neurotoxicity. PATIENTS AND METHODS: Prospective brain magnetic resonance imaging was performed at four time points for 369 children with ALL treated in a contemporary study that included five courses of high-dose MTX and 13 to 25 doses of triple intrathecal therapy. Logistic regression modeling was used to evaluate clinical and pharmacokinetic factors, and a genome-wide association study (GWAS) was performed to identify germline polymorphisms for their association with neurotoxicities. RESULTS: Fourteen patients (3.8%) developed MTX-related clinical neurotoxicity. Of 13 patients rechallenged with intrathecal and/or high-dose MTX, 12 did not experience recurrence of neurotoxicity. Leukoencephalopathy was found in 73 (20.6%) of 355 asymptomatic patients and in all symptomatic patients and persisted in 74% of asymptomatic and 58% of symptomatic patients at the end of therapy. A high 42-hour plasma MTX to leucovorin ratio (measure of MTX exposure) was associated with increased risk of leukoencephalopathy in multivariable analysis (P = .038). GWAS revealed polymorphisms in genes enriched for neurodevelopmental pathways with plausible mechanistic roles in neurotoxicity. CONCLUSION: MTX-related clinical neurotoxicity is transient, and most patients can receive subsequent MTX without recurrence of acute or subacute symptoms. All symptomatic patients and one in five asymptomatic patients develop leukoencephalopathy that can persist until the end of therapy. Polymorphisms in genes related to neurogenesis may contribute to susceptibility to MTX-related neurotoxicity.
PURPOSE:Methotrexate (MTX) can cause significant clinical neurotoxicity and asymptomatic leukoencephalopathy. We sought to identify clinical, pharmacokinetic, and genetic risk factors for these MTX-related toxicities during childhood acute lymphoblastic leukemia (ALL) therapy and provide data on safety of intrathecal and high-dose MTX rechallenge in patients with neurotoxicity. PATIENTS AND METHODS: Prospective brain magnetic resonance imaging was performed at four time points for 369 children with ALL treated in a contemporary study that included five courses of high-dose MTX and 13 to 25 doses of triple intrathecal therapy. Logistic regression modeling was used to evaluate clinical and pharmacokinetic factors, and a genome-wide association study (GWAS) was performed to identify germline polymorphisms for their association with neurotoxicities. RESULTS: Fourteen patients (3.8%) developed MTX-related clinical neurotoxicity. Of 13 patients rechallenged with intrathecal and/or high-dose MTX, 12 did not experience recurrence of neurotoxicity. Leukoencephalopathy was found in 73 (20.6%) of 355 asymptomatic patients and in all symptomatic patients and persisted in 74% of asymptomatic and 58% of symptomatic patients at the end of therapy. A high 42-hour plasma MTX to leucovorin ratio (measure of MTX exposure) was associated with increased risk of leukoencephalopathy in multivariable analysis (P = .038). GWAS revealed polymorphisms in genes enriched for neurodevelopmental pathways with plausible mechanistic roles in neurotoxicity. CONCLUSION:MTX-related clinical neurotoxicity is transient, and most patients can receive subsequent MTX without recurrence of acute or subacute symptoms. All symptomatic patients and one in five asymptomatic patients develop leukoencephalopathy that can persist until the end of therapy. Polymorphisms in genes related to neurogenesis may contribute to susceptibility to MTX-related neurotoxicity.
Authors: Kevin R Krull; Deepa Bhojwani; Heather M Conklin; Deqing Pei; Cheng Cheng; Wilburn E Reddick; John T Sandlund; Ching-Hon Pui Journal: J Clin Oncol Date: 2013-05-06 Impact factor: 44.544
Authors: Tobias Freilinger; Verneri Anttila; Boukje de Vries; Rainer Malik; Mikko Kallela; Gisela M Terwindt; Patricia Pozo-Rosich; Bendik Winsvold; Dale R Nyholt; Willebrordus P J van Oosterhout; Ville Artto; Unda Todt; Eija Hämäläinen; Jèssica Fernández-Morales; Mark A Louter; Mari A Kaunisto; Jean Schoenen; Olli Raitakari; Terho Lehtimäki; Marta Vila-Pueyo; Hartmut Göbel; Erich Wichmann; Cèlia Sintas; Andre G Uitterlinden; Albert Hofman; Fernando Rivadeneira; Axel Heinze; Erling Tronvik; Cornelia M van Duijn; Jaakko Kaprio; Bru Cormand; Maija Wessman; Rune R Frants; Thomas Meitinger; Bertram Müller-Myhsok; John-Anker Zwart; Markus Färkkilä; Alfons Macaya; Michel D Ferrari; Christian Kubisch; Aarno Palotie; Martin Dichgans; Arn M J M van den Maagdenberg Journal: Nat Genet Date: 2012-06-10 Impact factor: 38.330
Authors: Winnie C W Chu; Ki-Wai Chik; Yu-Leung Chan; David K W Yeung; Derek J Roebuck; Robert G Howard; Chi-Kong Li; Constantine Metreweli Journal: Radiology Date: 2003-10-23 Impact factor: 11.105
Authors: M Oka; S Terae; R Kobayashi; Y Sawamura; K Kudoh; K K Tha; M Yoshida; M Kaneda; Y Suzuki; K Miyasaka Journal: Neuroradiology Date: 2003-05-22 Impact factor: 2.804
Authors: Jennifer L Pauley; John C Panetta; Kristine R Crews; Deqing Pei; Cheng Cheng; John McCormick; Scott C Howard; John T Sandlund; Sima Jeha; Raul Ribeiro; Jeffrey Rubnitz; Ching-Hon Pui; William E Evans; Mary V Relling Journal: Cancer Chemother Pharmacol Date: 2013-06-13 Impact factor: 3.333
Authors: Hauke Rühs; Achim Becker; Anne Drescher; John C Panetta; Ching-Hon Pui; Mary V Relling; Ulrich Jaehde Journal: PLoS One Date: 2012-09-25 Impact factor: 3.240
Authors: Robert J Hayashi; Stuart S Winter; Kimberly P Dunsmore; Meenakshi Devidas; Zhiguo Chen; Brent L Wood; Michelle L Hermiston; David T Teachey; Sherrie L Perkins; Rodney R Miles; Elizabeth A Raetz; Mignon L Loh; Naomi J Winick; William L Carroll; Stephen P Hunger; Megan S Lim; Thomas G Gross; Catherine M Bollard Journal: J Clin Oncol Date: 2020-06-17 Impact factor: 44.544
Authors: Blake S Moses; William L Slone; Patrick Thomas; Rebecca Evans; Debbie Piktel; Peggi M Angel; Callee M Walsh; Pamela S Cantrell; Stephanie L Rellick; Karen H Martin; James W Simpkins; Laura F Gibson Journal: Exp Hematol Date: 2015-09-25 Impact factor: 3.084
Authors: N D Sabin; Y T Cheung; W E Reddick; D Bhojwani; W Liu; J O Glass; T M Brinkman; S N Hwang; D Srivastava; C-H Pui; L L Robison; M M Hudson; K R Krull Journal: AJNR Am J Neuroradiol Date: 2018-09-13 Impact factor: 3.825
Authors: Slim Fellah; Yin T Cheung; Matthew A Scoggins; Ping Zou; Noah D Sabin; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson; Robert J Ogg; Kevin R Krull Journal: J Natl Cancer Inst Date: 2019-02-01 Impact factor: 13.506